BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rabies Vaccines With Isconova's Matrix-M™ Adjuvant Launched in Russia


2/8/2012 9:45:13 AM

UPPSALA, February 8, 2012 -- Isconova AB announces that its partner, VetBioChem, has launched two new dog and cat rabies vaccines on the Russian market. Both vaccines contain Isconova’s Matrix-MTMVet adjuvant, and Isconova will receive production revenues and royalties on sales.

Since 2010 Isconova and VetBioChem, a leading Russian animal health company, have collaborated on the development of rabies vaccines for dogs and cats, and these vaccines, Rabix and Rabifel, are the first marketed veterinary vaccines using Isconova’s adjuvant Matrix-M™Vet. The agreement with VetBioChem includes revenues for Isconova for the supply of Matrix-M™Vet as well as royalties based on future sales of the rabies vaccines.

Russell Greig, acting CEO of Isconova, commented;

“We are very pleased that Rabix and Rabifel have been launched in Russia where rabies is a serious problem for both animals and humans. The launch of these Matrix-M™ based vaccines is further validation of our adjuvant technology platform and marks another step towards launching additional vaccines based on Isconova’s enabling technology in new markets.”

For more information, please contact:

Gerd Rundström, COO, Isconova AB

Tel +46 18 16 17 06, e-mail: gerd.rundstrom@isconova.com

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.

Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.com

About VetBioChem

VetBioChem (NPO Narvac) is a leading animal health company in Russia. VetBioChem produces vaccines, diagnostics and therapeutics for cattle, pigs and companion animals. www.vetbiochem.com

About Matrix-M™

Matrix-M™ is Isconova’s patented adjuvant for use in vaccines for humans and some animals, antibody production and immunological research. Matrix-M™Vet is used in animal vaccines.

About adjuvants

Adjuvants are substances that improve the efficacy and duration of protection of vaccines.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES